Catalog No.
Product Name
Application
Product Information
Citations
-
hERG Inhibitor
ERG-IN-5 is a potent hERG potassium channel inhibitor, demonstrating an IC50 value of 1.5 μM. This compound exhibits significant cytotoxicity towards MTAPdel HCT116 cells, with a CC50 of 28 nM. ERG-IN-5 is valuable for research applications focused on colon cancer, facilitating the exploration of mechanisms related to potassium channel modulation and cancer cell viability. -
Potassium Channel Blocker
Kaliotoxin (1-37) is a calcium-dependent potassium channel blocker derived from the venom of the scorpion Androctonus mauretanicus. This peptide demonstrates potent inhibition of potassium channels, making it a valuable tool for research into neuronal excitability and muscle contraction mechanisms. It is widely utilized in studies exploring ion channel function, neurophysiology, and potential therapeutic applications in cardiac and neurological disorders. -
Potassium Channel
SKF 95601 is a modulator of small conductive Ca2+-activated K+ channels, exhibiting anti-atrial fibrillation (AF) activity. This compound may inhibit atrial fibrillation by influencing the relationship between intracellular Ca2+ concentration and membrane potential. Due to its substantial expression in multiple species, particularly in human atria, SKF 95601 serves as a significant target for research into atrial fibrillation therapeutics. -
Potassium Channel
CM-TPMF is a modulator of the K(Ca)2.1 potassium channel, exhibiting selective activation and inhibition based on its stereochemical structure. This compound serves as both an activator and inhibitor of K(Ca)2.1 channels, making it valuable for investigating their physiological and pathophysiological roles in various biological contexts. CM-TPMF is an essential reagent for research aimed at understanding potassium channel dynamics and their implications in cellular signaling pathways. -
HERG Channel Inhibitor
GPV574 is a potent inhibitor of the HERG potassium channels, with an IC50 value of 5.04 μM. This compound is a derivative of the antiarrhythmic agent propafenone and is employed in research investigating cardiac electrophysiology and drug-induced arrhythmias. Its ability to modulate ion channel activity makes it a valuable tool in the study of heart rhythm disorders. -
Potassium Channel Inhibitor
Stromatoxin 1 is a selective inhibitor of potassium channels, specifically targeting K(V)2.1, K(V)2.2, and K(V)4.2 subunits. This peptide, derived from tarantulas, has been shown to effectively modulate smooth muscle contractions in the urinary bladder by inhibiting the activity of K(V)2.1 and K(V)2.2 channels, while having no effect on K(V)4.2. It serves as a valuable tool for research into bladder physiology and the electrophysiological properties of potassium channels. -
TREK-2 Activator
11-Deoxyprostaglandin F2α is a selective activator of TREK-2 channels, exhibiting an EC50 of 0.294 μM. This compound has been shown to modulate potassium ion conductance, making it valuable in studies of ion channel physiology and neurobiology. Additionally, 11-Deoxyprostaglandin F2α serves as an inhibitor of the K2P channel TREK-1, thereby providing insights into the functional differences between TREK channel subtypes. -
hERG Channels Blocker
E-4031 free base is a selective blocker of the hERG potassium channels, primarily involved in cardiac action potential repolarization. This compound is essential for studying the mechanisms of class III anti-arrhythmic agents and their effects on cardiac rhythm and arrhythmia. Its specificity for hERG channels makes it a valuable tool for investigating the pharmacological profiles of various therapeutic candidates in cardiological research. -
Potassium Channel Agonist
RWJ 29009 is a selective agonist of ATP-sensitive potassium channels. It activates these channels in vascular smooth muscle cells, facilitating potassium efflux and membrane hyperpolarization, resulting in coronary and peripheral vasodilation. This reagent is valuable for investigating cardiovascular diseases, including acute myocardial ischemia and hypertension. -
Kv7.2 Modulator
Kv7.2 Modulator 1 is a selective modulator of Kv7.2 ion channels, primarily involved in regulating neuronal excitability. It exhibits potential antiepileptic activity, making it a valuable tool for epilepsy research. This compound can be utilized to investigate the mechanistic pathways of seizure disorders and assess therapeutic strategies targeting Kv7.2 channels. -
Kv1.3 Blocker
ShK-Dap22 is a highly selective Kv1.3 channel blocker, exhibiting potent immunosuppressive properties with IC50 values of 23 pM for mKv1.3, 1.8 nM for mKv1.1, 10.5 nM for hKv1.6, 37 nM for mKv1.4, and 39 nM for rKv1.2. This polypeptide is primarily utilized in research focused on autoimmune diseases and T cell modulation, enhancing the understanding of Kv1.3's role in immune responses. Its high specificity for Kv1.3 makes it a valuable tool for investigating immune cell function and potential therapeutic pathways. -
Antiarrhythmic Agent
Tedisamil dihydrochloride is an antiarrhythmic agent primarily targeting the transient outward potassium current (I(to)) in cardiac tissue. This compound significantly slows heart rate by inhibiting multiple potassium channels, including IK, K(ATP), and PKA-activated chloride channels, which prolongs the cardiac action potential and QT interval. Tedisamil dihydrochloride is effective in demonstrating antiarrhythmic effects against ventricular arrhythmias and atrial flutter in various animal models, making it a valuable tool for cardiovascular research. -
Maxi-K Channel Modulator
Maxi-K modulator 1 is a modulator of the Maxi-K channel, a large conductance calcium-activated potassium channel. This compound exerts a significant stimulatory effect on Maxi-K channel activity, promoting potassium efflux. Maxi-K modulator 1 is particularly useful in research related to fragile X syndrome and other neurological disorders involving channelopathies. -
Kv1.3 Blocker
Nalanthalide is a selective blocker of the voltage-gated potassium channel Kv1.3, exhibiting an IC50 of 3.9 µM. It demonstrates potential as an immunosuppressant, making it valuable in the study of inflammatory immune diseases. This compound is particularly relevant for research involving neuroinflammation and related pathologies. -
hERG Channel Inhibitor
5-O-Desmethyl donepezil is a metabolite of Donepezil that functions as an inhibitor of the hERG potassium channel with an IC50 of 1.5 μM. This compound is particularly relevant for studies examining cardiac ion channel activity and drug interactions affecting cardiac repolarization. Its potential applications include assessing safety profiles for drug candidates in pharmacological research. -
Potassium Channel Blocker
AM 92016 is a potent potassium channel blocker that modulates ion flow, thereby increasing the duration of action potentials in isolated ventricular cells from guinea pigs and rabbits. This compound has been shown to exhibit proarrhythmic activity in guinea pigs and pigs, making it a valuable tool for studying cardiac electrophysiology and potential arrhythmogenic effects. It is suitable for research applications focused on cardiac function and the behavior of ion channels in the heart. -
Kv1.5. Potassium Channel Inhibitor
RH01617 is a selective inhibitor of the Kv1.5 potassium channel, known to modulate cardiac repolarization. This compound exhibits potential for research applications related to atrial fibrillation and other cardiovascular disorders. Additionally, RH01617 also functions as an MMP-13 inhibitor, suggesting a broader scope of biological activity in tissue remodeling processes. -
Potassium Channel Activator
Dihydroisopimaric acid is a potent activator of large conductance calcium-activated potassium (BK) channels, specifically targeting the BKαβ1 subunit. This compound has been demonstrated to effectively enhance the opening of BK channels under whole-cell voltage clamp conditions. Its key biological activity makes it a valuable tool for investigating the role of potassium channels in various physiological processes and in the study of cardiovascular and neurological disorders. -
Potassium Ionophore
Potassium Ionophore III (BME-44) functions as a selective potassium ion carrier, demonstrating high specificity for sodium and ammonium ions due to its pronounced lipophilic properties. This compound is primarily utilized in research settings for the study of potassium transport and ion homeostasis in cellular systems. Its efficacy in modulating ion concentrations makes it a valuable tool for investigating the physiological and pathological roles of potassium ions in various biological processes. -
KV1.3 Channel Inhibitor
ShK toxin is a potent inhibitor of the voltage-dependent potassium channel (Kv1.3), derived from the Caribbean sea anemone Stichodactylus helianthus. This toxin competitively interacts with dendrotoxin I and α-dendrotoxin at synaptosomal membranes, enhancing acetylcholine release. In addition to its neural effects, ShK toxin effectively suppresses K+ currents in cultured rat dorsal root ganglion neurons and demonstrates significant inhibition of T lymphocyte proliferation. It serves as a valuable tool in studies of neurophysiology and immunology. -
Kir2 Inhibitor
ML-133 is a selective inhibitor of the Kir2 family of potassium channels, exhibiting an IC50 of 1.8 μM at pH 7.4 and 290 nM at pH 8.5. This compound serves as a valuable tool for investigating the role of Kir2 channels in various physiological processes and pathophysiological conditions. Its ability to modulate potassium ion flow makes it applicable in studies related to cardiac function, neuronal signaling, and other cellular activities influenced by Kir2 channel activity. -
Potassium Channel Activator
SG-209 is a potassium channel activator derived from Nicorandil, known for its ability to induce smooth muscle relaxation. This compound facilitates vasodilation through its action on potassium channels, contributing to enhanced tracheal smooth muscle relaxation. Research applications of SG-209 include studies on respiratory physiology and vascular function, particularly in animal models where it has been shown to increase tracheal blood flow. -
KCNE2/KCNQ1 Potassium Channel Blocker
IKs124 is a potent inhibitor of the KCNE2/KCNQ1 potassium channel, exhibiting an IC50 value of 8 nM. This compound is valuable for investigating the role of potassium channels in various biological processes, particularly in the context of peptic ulcer studies. Its selective blockade of these channels makes it an essential tool for research into gastrointestinal disorders and related therapies. -
Kv 1.5 Inhibitor
BMS-394136 is a selective inhibitor of the Kv 1.5 potassium channel, exhibiting an IC50 of 0.05 μM. This compound effectively prolongs the atrial effective refractory period (AERP) and action potential duration (APD) in a dose-dependent manner while leaving the ventricular effective refractory period (VERP) unaffected. BMS-394136 is particularly useful for research focused on acute atrial ischemia and related cardiac electrophysiological studies. -
Potassium Channel Activator
KR-30450 is a potent potassium channel activator with a specific action as a K+ ATP opener. It demonstrates significant cardioprotective effects, outperforming Lemakalim in enhancing reperfusion cardiac function. Additionally, KR-30450 effectively reduces reperfusion contracture and the release of lactate dehydrogenase, making it valuable for research in cardiac protection and ischemia-reperfusion injury studies. -
hSK1 Bloker
UCL-1848 TFA is a potent blocker of the human small conductance calcium-activated potassium channel (hSK1), exhibiting an IC50 value of 1.1 nM. This compound is valuable for studies focused on the modulation of hSK1 activity and its role in cellular signaling pathways. Research applications include investigations into excitability in neurons and cardiac tissues, as well as potential therapeutic implications in various neurological and cardiovascular disorders. -
Ion Channel Inhibitor
Nerispirdine is an ion channel inhibitor that selectively targets voltage-gated potassium channels K(v)1.1 and K(v)1.2, exhibiting IC50 values of 3.6 µM and 3.7 µM, respectively, and also inhibits voltage-dependent sodium channels with an IC50 of 11.9 µM. As a derivative of 4-aminopyridine, Nerispirdine serves as a valuable tool in the investigation of neurological disorders, contributing to research focused on channelopathies and synaptic transmission. Its potential for modulating ion channel activity makes it a significant compound for studying electrophysiological processes. -
Potassium Channel
Lombazole is an antimicrobial agent that primarily targets potassium channels and inhibits lipid synthesis in bacterial membranes. It exhibits selective antibacterial activity by disrupting the de novo synthesis of cell enclosure in Staphylococcus aureus without significantly affecting potassium permeability. Additionally, Lombazole interferes with the sterol C-14 demethylation process in Candida albicans, highlighting its potential applications in studying membrane dynamics and lipid biosynthesis in infectious pathogens. This compound is valuable for researchers investigating membrane integrity and antimicrobial resistance mechanisms. -
Potassium Channel Blocker
Besipirdine hydrochloride is a potassium channel blocker that exerts both cholinergic and adrenergic effects. Its cholinergic activity is characterized by stimulation of phosphatidylinositol turnover and a reduction in potassium currents, while its adrenergic activity promotes norepinephrine release through the inhibition of presynaptic α2-adrenergic receptors and the blocking of norepinephrine reuptake. This compound is applicable in research related to Alzheimer's disease, providing insights into potential therapeutic pathways. -
Chemical Modulator Of KCNQ Channel
ztz240 is a chemical modulator targeting the voltage-gated potassium channel Kv7 (KCNQ), specifically KCNQ2 and KCNQ3 with an EC50 of 6.1 μM, and KCNQ4 with an EC50 of 12.2 μM. This compound exhibits significant biological activity relevant to analgesia and anti-epileptic research. Its modulation of KCNQ channels makes it a valuable tool for studying the underlying mechanisms of pain and seizure disorders. -
Kv1.5 Channel Inhibitor
MSD-D is a potent Kv1.5 channel inhibitor, exhibiting a frequency-dependent mechanism with an IC50 value of 0.5 μM. This compound is promising for research into atrial-selective class III antiarrhythmics, offering potential insights into cardiac arrhythmias and related therapies. -
Stable Isotope
Flecainide-d3 is a deuterium-labeled form of Flecainide, a clinically utilized antiarrhythmic agent. Its primary mechanism involves blocking sodium channels while also inhibiting calcium ion release through the cardiac ryanodine receptor (RyR2). This reagent is valuable in research focused on cardiac arrhythmias, particularly in the study of catecholaminergic polymorphic ventricular tachycardia (CPVT) and related cardiac conditions. Its stable isotope labeling facilitates advanced pharmacokinetic and metabolic studies. -
hERG Inhibitor
6-O-Desmethyl donepezil is a potent hERG channel inhibitor, exhibiting an IC50 value of 1 μM. As a metabolite of Donepezil, it is instrumental in studying cardiac ion channel activity and the potential implications of drug interactions. This compound is valuable for research in cardiotoxicity and pharmacology, particularly in the context of drug development and assessment of cardiac safety profiles. -
bTREK-1 Potassium Channel Inhibitor
6-Bnz-cAMP (N6-Benzoyl-cAMP) is a potent inhibitor of the bTREK-1 potassium channel, functioning through a protein kinase A (PKA) independent mechanism. This compound is instrumental in investigating the roles of signal transduction proteins within the cAMP signaling pathway. Its use can aid in elucidating the physiological and pathophysiological processes mediated by bTREK-1 and cAMP-related signaling cascades. -
Potassium Channel Inhibitor
(BrMT)2 is a non-peptide potassium channel inhibitor that primarily targets Kv1.1 channels. It effectively slows the activation kinetics of these channels, making it a valuable tool for elucidating the physiological roles of potassium channels in various cellular processes. This compound is useful in research applications focusing on neurophysiology, cardiac function, and other studies involving ion channel modulation. -
Potassium Channel
(S)-PF 03716556 is a potassium channel inhibitor that functions as a K+-competitive acid blocker, exhibiting gastric acid pump inhibitory activity. This compound is utilized in research to study disease states influenced by gastric acid secretion, providing insights into potential therapeutic approaches for acid-related conditions. -
Potassium Channel KV1.5 Blocker
Mephetyl tetrazole is a potent potassium channel KV1.5 blocker with an IC50 of 330 nM. This compound is useful in cancer research, providing insights into the role of KV1.5 in tumor cell proliferation and survival. Its inhibition of KV1.5 channels may help elucidate the biochemical pathways that are altered in various cancer types, facilitating the development of targeted therapeutic strategies. -
Antiarrhythmic Agent
Nifekalant is a class III antiarrhythmic agent that functions as a blocker of IKr potassium channels, exhibiting an IC50 value of 10 μM. This compound is primarily utilized in research focused on refractory ventricular tachyarrhythmias, providing valuable insights into cardiac rhythm management. Its ability to modulate potassium channel activity makes it an essential tool for studying arrhythmic conditions and potential therapeutic interventions. -
Potassium Channel Activator
Phe-Met-Arg-Phe, amide is a potent potassium channel activator that reliably elicits K+ current activation in peptidergic caudodorsal neurons, with an effective dose (ED50) of 23 nM. This compound is critical for studies involving ion channel modulation and neuronal signaling, making it an essential tool in neurobiology research and pharmacological investigations. -
Potassium Channel Activator
KRN4884 is a potassium channel activator that stimulates KATP channels in the presence of intracellular ATP at a concentration of 1 mM. It enhances channel activity in a concentration-dependent manner, with an EC50 value of 0.55 μM. This compound is useful for researchers investigating the physiological roles of KATP channels and their implications in cellular signaling and metabolic regulation. -
Potassium Channel Inhibitor
CS476 is a potent inhibitor of potassium channels, exhibiting significant hypoglycemic activity. This compound may facilitate research into the modulation of glucose homeostasis and has potential applications in the study of diabetes-related pathways. Its ability to influence potassium channel activity makes it a valuable tool for investigating various cellular processes linked to metabolic regulation. -
Potassium Channel Activator
Potassium Channel Activator 1 is a selective potassium channel activator that facilitates the opening of potassium channels, contributing to membrane potential regulation. This compound exhibits significant biological activity that may influence cellular excitability and neurotransmitter release. It is primarily utilized in research focused on dopaminergic system disorders, providing insights into potential therapeutic strategies for neurological and psychiatric conditions. -
Potassium Channel
U89232 is a selective opener of the ATP-sensitive potassium (KATP) channels. This compound primarily acts on cardiac tissues, promoting vasodilation and potentially offering protective effects against ischemic conditions. It is valuable for research into cardiovascular pharmacology and the modulation of KATP channels in various therapeutic contexts. -
Proton Pump Inhibitor
Zastaprazan citrate is a proton pump inhibitor that functions as a potent potassium-competitive acid blocker. This compound is primarily utilized in research related to gastrointestinal inflammatory disorders and gastric acid-related conditions, including gastroesophageal reflux disease. Its ability to effectively inhibit gastric acid secretion makes it a valuable tool for studying underlying mechanisms of these diseases. -
Proton Pump Inhibitor
Azeloprazole sodium is a potent proton pump inhibitor (PPI) that effectively reduces gastric acid secretion. This compound is primarily used in research related to gastroesophageal reflux disease (GERD), facilitating studies on acid-related gastrointestinal disorders and therapeutic interventions. Its mechanism of action provides valuable insights into the regulation of gastric proton pumps and their role in acid-mediated conditions. -
Potassium-Competitive Acid Blocker
Vonoprazan Fumarate is a potent potassium-competitive acid blocker (P-CAB) that exerts its effect by inhibiting H+,K+-ATPase activity, demonstrating an IC50 of 19 nM at pH 6.5 in porcine gastric microsomes. This compound exhibits significant antisecretory activity, making it valuable for investigating acid-related disorders. Research applications include studies related to gastroesophageal reflux disease and peptic ulcer disease, where it may provide insights into therapeutic mechanisms. -
PM Ca2+-ATPase Inhibitor
Caloxin 2A1 is a selective inhibitor of the plasma membrane Ca2+-ATPase (PMCA), functioning at the extracellular level. This peptide demonstrates a targeted inhibition of PMCA activity without influencing basal Mg2+-ATPase or Na+-K+-ATPase activity. It serves as a valuable tool in studies investigating calcium homeostasis and its implications in cellular signaling and physiology. -
Proton Pump/Potassium-competitive Acid Inhibitor
Abeprazan hydrochloride is a potassium-competitive acid inhibitor that selectively targets H+, K+-ATPase, providing a mechanism of action distinct from traditional proton pump inhibitors. By reversibly binding in a potassium-competitive manner, Abeprazan hydrochloride effectively reduces gastric acid secretion without requiring acid activation. This compound is being investigated for its therapeutic potential in treating various acid-related gastrointestinal disorders. -
Proton Pump/Potassium-competitive Acid Inhibitor
Abeprazan is a potassium-competitive acid inhibitor primarily targeting the H+, K+-ATPase enzyme. By reversibly binding to this enzyme through potassium-competitive ionic interactions, it effectively reduces gastric acid secretion without the need for acid activation. Abeprazan is being developed as a potential alternative to traditional proton pump inhibitors for the management of acid-related disorders, providing a novel approach to acid control in clinical applications. -
v-ATPase Inhibitor
Verucopeptin is a selective v-ATPase inhibitor that targets the ATP6V1G subunit, effectively reducing v-ATPase activity. This compound has a notable impact on HIF-1 signaling, decreasing the expression of HIF-1α and its target genes. Additionally, Verucopeptin demonstrates antitumor properties against multidrug resistant (MDR) cancers, making it a valuable tool for cancer research. Its specific mechanism and biological activity position it as a significant reagent for studies focused on tumor biology and therapy resistance.
